The constituent tryptophans and bisANS as fluorescent probes of the active site and of a secondary binding site of stromelysin-1 (MMP-3).
The active site of the catalytic domain of stromelysin-1 (matrix metalloproteinase-3, MMP-3) was probed by fluorescence quenching, lifetime, and polarization of its three intrinsic tryptophans and by the environmentally sensitive fluorescent reporter molecule bisANS. Wavelength-dependent acrylamide quenching identified three distinct emitting tryptophan species, only one of which changes its emission and fluorescence lifetime upon binding of the competitive inhibitor Batimastat. Significant changes in the tryptophan fluorescence polarization occur upon binding by any of the three hydroxamate inhibitors Batimastat, CAS108383-58-0, and Celltech CT1418, all of which bind in the P2'-P3' region of the active site. In contrast, the inhibitor CGS27023A, which is thought to bind in the P1-P1' region, does not induce any change in tryptophan fluorescence polarization. The use of the fluorescent probe bisANS revealed the existence of an auxiliary binding site extrinsic to the catalytic cleft. BisANS acts as a competitive inhibitor of stromelysin with a dissociation constant of Ki=22 microM. In addition to this binding to the active site, it also binds to the auxiliary site with a dissociation constant of 3.40+/-0.17 microM. The auxiliary site is open, hydrophobic, and near the fluorescing tryptophans. The binding of bisANS to the auxiliary site is greatly enhanced by Batimastat, but not by the other competitive inhibitors tested.
Epps
D E
DE
Pharmacia and Upjohn Company, Kalamazoo, Michigan 49001, USA.
Poorman
R A
RA
Petzold
G L
GL
Stuchly
C W
CW
Laborde
A L
AL
Van Drie
J H
JH
D000178:Acrylamides; D000817:Anilino Naphthalenesulfonates; D001665:Binding Sites; D020134:Catalytic Domain; D005454:Fluorescence Polarization; D005456:Fluorescent Dyes; D006877:Hydroxamic Acids / Q000494:pharmacology; D019278:Matrix Metalloproteinase 3 / Q000737:chemistry* / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D008956:Models, Chemical; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D011485:Protein Binding; D011719:Pyrazines; D013050:Spectrometry, Fluorescence; D013449:Sulfonamides / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology; D014364:Tryptophan
D000178:Acrylamides; D000817:Anilino Naphthalenesulfonates; C097658:CGS 27023A; C117729:CT 1418; D005456:Fluorescent Dyes; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; D011480:Protease Inhibitors; D011719:Pyrazines; D013449:Sulfonamides; D013876:Thiophenes; C117730:3-((benzyl)(methylaminocarbonyl)methylaminocarbonyl)N-hydroxy-5-methylhexanamide; D010649:Phenylalanine; C035763:5,5'-bis(8-(phenylamino)-1-naphthalenesulfonate); D014364:Tryptophan; C080985:batimastat; D019278:Matrix Metalloproteinase 3